Erythropoietin (EPO), a hematopoietic neurotrophin, is a potential therapeutic for Alzheimer’s disease (AD) but has limited blood–brain barrier (BBB) permeability. This evidence concerns the gene BDNF and early-onset autosomal dominant Alzheimer disease.